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Babik B, Balogh AL, Sudy R, Ivankovitsne-Kiss O, Fodor GH,
Petak F. Levosimendan prevents bronchoconstriction and adverse
respiratory tissue mechanical changes in rabbits. Am J Physiol Lung
Cell Mol Physiol 313: L950–L956, 2017. First published August 24,
2017; doi:10.1152/ajplung.00213.2017.—Levosimendan has a calc-
ium-sensitizing effect in the myocardium and opens ATP-sensitive
potassium channels (KATP) in vascular smooth muscle. Because
airway smooth muscle also expresses KATP, we characterized the
protective potential of levosimendan against increased airway and
respiratory tissue resistances. Animals were administered levosimen-
dan alone (group L), levosimendan after pretreatment with a KATP
channel blocker (glibenclamide, group LG), glibenclamide only
(group G), or solvent alone (dextrose, group C). Airway resistance
(Raw), tissue damping, and elastance were determined by forced
oscillations under baseline conditions and following provocation tests
with intravenous methacholine (MCh). Cardiac output (CO) was
assessed by transpulmonary thermodilution. The same sequence of
measurements was then repeated during intravenous infusion of levo-
simendan in groups L and LG or glucose in groups G and C. Sham
treatments in groups C and G had no effect on lung responsiveness.
However, levosimendan treatment in group L elevated CO and inhib-
ited the MCh-induced airway responses [Raw changes of 87.8 83%
(SD) vs. 24.4  16% at 4 g·kg1·min1 MCh, P 0.001], and in G
(35.2 12.7 vs. 25.2 12.9%, P  0.05). The preventive affect of
levosimendan against lung constriction vanished in the LG group.
Levosimendan exerts a KATP-mediated potential to prevent broncho-
constriction and may prohibit adverse lung peripheral changes both in
the small bronchi and the pulmonary parenchyma. The identification
of a further pleiotropic property of levosimendan that is related to the
pulmonary system is of particular importance for patients with de-
creased cardiorespiratory reserves for which simultaneous circulatory
support is complemented with prevention of adverse respiratory
events.
bronchodilator agents; bronchoconstriction; cardiovascular drugs; car-
diac inotropism; respiratory mechanics
LEVOSIMENDAN IS AN inodilator recommended for the treatment
of acute (38) and chronic (29) heart failure. Its positive ino-
tropic effect is attributed to Ca2 sensitization, which is
achieved by the stabilization of the Ca2-bound conformation
of cardiac troponin C (18). Levosimendan provides a well-
established advantage: its use does not increase intracellular
cAMP while elevating intracellular Ca2 (11). Thus, myocar-
dial contractility is facilitated without an increase in oxygen
demand and without provoking malignant tachyarrhythmias
(11). These processes are responsible for the elevations in
cardiac output (CO) and improved myocardial oxygen balance
(3, 10, 21), without compromising mean arterial pressure
(MAP) (44).
Another key feature of levosimendan is the opening of
ATP-sensitive potassium (KATP) channels in smooth muscle
cells (31, 37). The activation of KATP channels induces an
efflux of K ions that results in decreased membrane potential
and, consequently, an inhibition of L-type calcium channels,
which leads to the relaxation of smooth muscle cells. This
mechanism has been demonstrated in arterial (16) and venous
(32) vascular smooth muscle cells (VSMC). Although KATP
channels are also expressed by airway smooth muscle cells
(ASMC) (6), there is an essential lack of knowledge about the
effects of levosimendan on the respiratory system.
To address this lack, we sought to determine the potential of
levosimendan to prevent the constrictor response of the respi-
ratory system by measuring airway mechanics and viscoelastic
properties of respiratory tissues in an animal model relevant to
a clinical scenario. To learn the underlying mechanism, we also
investigated the role of KATP channels in the bronchoprotective
effects of levosimendan. We hypothesize that levosimendan is
able to inhibit constriction at the level of contractile elements
embedded in both the airways and lung parenchyma, and the
KATP channels mediate this effect. Glibenclamide was applied
to verify the involvement of the KATP channels in the pulmo-
nary effect of levosimendan, since glibenclamide selectively
inhibits KATP channel activity without affecting contractility of
the myocardium.
MATERIALS AND METHODS
This study was approved by the Experimental Ethics Committee of
the University of Szeged, Szeged, Hungary, on the 7th of December
2012 (no. I-74-50/2012), and authorized by the National Food Chain
Safety and Animal Health Directorate of Csongrád County, Hungary
(no. XIV/152/2013, Chairperson Cs. Farle), on the 9th of January
2013. The procedures were performed according to the guidelines of
the Scientific Committee of Animal Experimentation of the Hungarian
Academy of Sciences [updated Law and Regulations on Animal
Protection: 40/2013 (II. 14.) Government of Hungary], following the
European Union Directive 2010/63/EU on the protection of animals
used for scientific purposes, and reported in compliance with the
ARRIVE guidelines.
Animal preparation. We performed experiments on male New
Zealand White rabbits (n  27, weighing 2.0–2.5 kg). The rabbits
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were sedated by an intramuscular injection of xylazine (5 mg/kg,
CP-xylazine; CP-Pharma, Burgdorf, Germany), and an intravenous
line was secured to the ear. Anesthesia induction was then performed
by an intravenous injection of pentobarbital sodium (30 mg/kg;
Sigma-Aldrich, Budapest, Hungary), and the rabbit was placed in a
supine position on a heating pad to maintain body temperature in the
38  0.5°C range. After endotracheal intubation by tracheostomy was
achieved, the rabbits were connected to a small animal ventilator
(model 683; Harvard Apparatus, South Natick, MA) and ventilated
with room air (ventilation frequency 40–50 min1, tidal volume 8
ml/kg). A femoral artery and femoral and jugular veins were cathe-
terized for drug delivery, blood pressure monitoring, and cardiac
output assessment. Anesthesia and neuromuscular blockade were
maintained by repeated (every 30 min) intravenous boluses of pento-
barbital sodium (5 mg/kg) and pipecuronium (0.3 mg/kg, Arduan;
Gedeon Richter, Budapest, Hungary), respectively.
Cardiovascular monitoring. Systemic hemodynamic parameters
were monitored by using a transpulmonary arterial thermodilution
system (PiCCO; PULSION Medical Systems, Feldkirchen, Ger-
many). A 3-ml thermal indicator bolus (8°C) was injected in the
right atrium via the central venous catheter inserted in the jugular
vein. A data acquisition and analysis system (BIOPAC, Goleta, CA)
was used to record continuous arterial pressure and heart rate (HR)
signals. The MAP was estimated as the diastolic blood pressure plus
a third of the pulse pressure.
Measurement of respiratory mechanics. A T piece with two col-
lapsible segments was connected to the tracheal tube. One end was
attached to the ventilator and the other to a loudspeaker-in-box system
of a forced oscillatory measurement apparatus. Mechanical ventilation
was halted for 8-s periods at end expiration, and a computer-generated
small-amplitude (less than1 cmH2O) pseudo-random signal con-
taining 23 sinusoidal components in the interval of 0.5–20.75 Hz was
delivered by the loudspeaker and introduced into the lungs. The
resulting gas flow (V=) was measured with a differential pressure
transducer (model 33NA002D; IC Sensors, Milpitas, CA). Tracheal
pressure was measured with an identical pressure transducer relative
to the atmosphere (P). The P and V= signals were low-pass filtered at
25 Hz and sampled with a data acquisition board (NI USB-6211;
National Instruments, Austin, TX) at a rate of 256 Hz. The input
impedance spectra of the respiratory system (Zrs) were calculated by
using a fast-Fourier transformation with 4-s time windows and 95%
overlap (Zrs  P/V=). The input impedance of the tracheal tube and
the connections were also measured and subtracted from the Zrs
spectra.
The mechanical properties of the airways and the respiratory
tissues were determined using model fitting by minimizing the
weighted difference of the measured and the modeled spectra. The
well-validated model (27) contained frequency-independent airway
resistance (Raw) and inertance (Iaw) connected in series to a constant-
phase tissue compartment incorporating damping (G) and elastance
(H) parameters (19). Raw represents primarily the resistance of the
conducting airways; Iaw is related to the mass of gas in the airways,
and its decrease indicates enhanced ventilation heterogeneities (35).
Parameters G and H indicate the resistive (i.e., damping or energy
loss) and elastic (i.e., stiffness) characteristics, respectively, of the
respiratory tissues, including the lung parenchyma and chest wall.
Experimental protocol. In the first control stage of the protocol,
four successive Zrs recordings were collected from all of the rabbits to
establish the baseline (Fig. 1). Provocation tests with increasing doses
(0.5, 1, 2, and 4 g·kg1·min1) of intravenous methacholine (MCh)
were performed on all of the animals. When a stable level of
constriction had been established, four Zrs data epochs were collected
during each MCh infusion rate. A 15-min recovery period was
allowed for the normalization of the respiratory and systemic hemo-
dynamic parameters, and a second set of baseline parameters was
measured. The rabbits were then randomly assigned to one of four
groups as follows: control (group C, n  9), levosimendan (group L,
n  10), glibenclamide (group G, n  6), and levosimendan 
glibenclamide (group LG, n  8). Animals in group C received the
solvent used for levosimendan (5% dextrose) in the same volumes as
for other groups for matching intervals. Rabbits in group G also
received 5% dextrose and an intraperitoneal injection of the KATP
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Fig. 1. Scheme of the experimental protocol. In the control phase, oscillatory measurements were performed at baseline (BL1) and for each step of the
methacholine (MCh) provocation with increasing doses (0.5, 1, 2, and 4 g·kg1·min1). After completing the MCh infusions (15 min), a second set of baseline
measurements was performed (BL2). Subsequently, glucose was infused in control (group C) and glibenclamide (G) groups at 5 ml·kg1·h1 for 15 min and
again at 1 ml·kg1·h1 for 135 min. Rabbits in group G received an ip injection of 25 mg glibenclamide (GLI). Levosimendan (LEV) dissolved in glucose was
administered to group L in matching volumes (50 g·kg1·h1 for 15 min initially and then 10 g·kg1·h1 for 135 min). In addition to the levosimendan
infusion, rabbits of group LG received an intraperitoneal injection of 25 mg glibenclamide. Provocations with MCh were then repeated in the same manner with
the maintained infusion of the corresponding agents (glucose or levosimendan) in all four groups.
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channel blocker glibenclamide (25 mg/kg) (20) (Sigma-Aldrich, St.
Louis, MO) dissolved in dimethyl sulfoxide. Levosimendan (SIMDAX;
Orion, Espoo, Finland) was infused in doses of 50 g·kg1·h1 for 15
min and then 10 g·kg1·h1 for 135 min in the animals assigned to
group L. In the rabbits in group LG, an intraperitoneal injection of
glibenclamide was applied before an identical levosimendan treat-
ment. In the treatment stage of the protocol, the MCh provocation test
was repeated in the same way as in the previous stage. CO was
assessed under the initial baseline conditions and at 15 and 150 min
after initiating the treatments. Ensemble-averaged Zrs spectra obtained
during each experimental stage were used to establish airway and
respiratory tissue mechanical parameters. The MCh doses eliciting a
25% increase in Raw relative to baseline (PD25) were determined by
fitting linear models to the individual dose-response curves; R2  0.8
was obtained for these linear models for each rabbit.
Statistical analysis. The scatter of the values of the measured
variables is presented as SD of the mean. The baseline characteristics
of the rabbits in the protocol groups were compared by using one-way
ANOVA tests on ranks. Three-way repeated-measures ANOVA was
used to assess the effects of group allocation (C, L, or LG), protocol
stage (control or treatment), and MCh dose (0.5, 1, 2, or 4
g·kg1·min1) on the changes in the respiratory mechanical param-
eters. Two-way ANOVA with repeated measures was used to com-
pare the hemodynamic indexes in the protocol groups at different time
points (0, 15, or 150 min after commencing each treatment), and the
PD25 values obtained in the two stages. Post hoc analyses were
performed using the Holm–Sidak multiple-comparisons procedure.
The association between changes in CO and MAP was assessed by a
Pearson product-moment correlation test. Sample size was estimated
for MCh-induced change in Raw as the primary outcome variable with
an expected 25% difference in the lung responsiveness, a power of
0.8, and two-sided 	-error of 0.05. The estimation resulted in a
required sample size of five for each group, based on the MCh-
induced changes in Raw in our earlier study (13). The statistical tests
were performed within the R core package with the lme4 (4) and
lsmeans (25) packages and SigmaPlot 13 (version 13; Systat Software,
Chicago, IL). The statistical tests were performed with a significance
level of P  0.05, and all P values were two sided.
RESULTS
There was no significant difference among the protocol groups
in the body mass or in the respiratory mechanical parameter
values obtained under the baseline conditions (Table 1).
Hemodynamic effects. In Fig. 2, we have plotted the sys-
temic hemodynamic parameter values under the baseline con-
ditions and at 15 and 135 min following each treatment,
according to the allocation of the animals to the protocol
groups. No significant differences were observed in any of the
systemic hemodynamic parameter values between the protocol
groups under the baseline conditions. Rabbits in groups C and
G exhibited no statistically significant changes in CO and
MAP; however, slight statistically significant increases were
observed in HR (P  0.001) only. In contrast, the similar rises
in HR (P  0.001) were associated with significant elevations
in CO (P  0.001 for both groups L and LG) and MAP (P 
0.001 and 0.003 for groups L and LG, respectively) in both
groups of animals receiving levosimendan treatment. At the
end of the protocol (150 min), CO values were significantly
higher in group L than that in the other three protocol groups
(P  0.05).
The relationship between the relative changes in CO and
MAP 150 min after initiating the treatment is depicted in Fig.
3 for each rabbit in the four protocol groups. There was a
statistically significant correlation between the percentage
changes of these systemic hemodynamic variables (r  0.71,
P  0.0001).
Respiratory mechanics. Figure 4 shows the alterations in the
MCh-induced responses in the airway (Raw and Iaw) and
respiratory tissue mechanical parameters (G and H) at two
stages of the experiment. No statistically significant difference
in airway or tissue constrictor responses was detected during
the control phase of the protocol. In the rabbits of groups C and
G, no difference was observed in the lung responses provoked
Table 1. Baseline characteristics for protocol groups
Group C Group G Group L Group LG P
Body wt, g 2,314  300 2,660  321 2,417  208 2,489  175 0.1
Raw, cmH2O·s·l1 13.0  3.3 11.1  2.7 12.1  1.9 14.8  5.7 0.3
Iaw, cmH2O·s2·ml1 43.4  36 41.7  15.4 33.1  13.0 57.0  16.4 0.2
G, cmH2O/l 141  16.5 140  24.0 130  21.2 159  31.1 0.1
H, cmH2O/l 631  75 632  171 660  101 667  212 0.9
Values are means  SD. Group C, control group that received solvent alone; group G, group that received glibenclamide; group L, group that received
levosimendan; group LG, group that received levosimendan  glibenclamide; Raw, airway resistance; Iaw, airway inertance; G, respiratory tissue damping; H,
respiratory tissue elastance.
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Fig. 2. Cardiac output (CO), mean arterial pressure
(MAP), and heart rate (HR) in groups C (white
circles), G (white squares), L (black circles), and LG
(black squares) under baseline conditions (BL) and at
15 and 150 min after commencement of treatment.
Error bars represent SE. P  0.05 vs. baseline within
a group (*) and vs. group L within a time point (#).
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by MCh at the two stages of the protocol, demonstrating the
reproducibility of the dose-response curves in these vehicle-
treated animals for both the presence (group G) and the
absence (group C) of glibenclamide treatment. In contrast,
levosimendan treatment in the animals of group L resulted in
significantly smaller responses in Raw and H at the three
highest MCh doses (P  0.03 and P  0.05, respectively), and
in G at the two highest MCh infusion rates (P  0.05). The
MCh-induced decreases in Iaw were reversed by levosimendan
treatment in the rabbits of group L (P  0.05). The inhibition
of lung responsiveness by levosimendan vanished in the glib-
enclamide-treated rabbits (group LG), i.e., the lung responsive-
ness to MCh did not differ before or after a combined gliben-
clamide-levosimendan treatment.
Figure 5 depicts the PD25 values for Raw determined from
the MCh dose-response curves for the three protocol groups.
During the first phase of the protocol (when no treatment was
applied), no significant differences were seen among the pro-
tocol groups. Levosimendan infusion led to a marked increase
in PD25 in group L (P  0.0001), whereas no significant
changes were observed in the C, G, and LG groups.
DISCUSSION
We used an in vivo animal model with clinical relevance to
characterize the effects of levosimendan on the respiratory
system. Our results revealed that the known circulatory effect
of levosimendan is associated with its marked protective po-
tential against bronchospasm and increases in the respiratory
tissue viscoelastic parameters induced by the exogenous ad-
ministration of a cholinergic constrictor agonist. The blockade
of KATP channels significantly reversed the ability of levosi-
mendan to inhibit the constrictive response of the lung, which
indicated the primary role of the KATP channels expressed by
contractile cells in the pulmonary system.
Systemic circulatory effects of levosimendan. In agreement
with the findings of previous experimental (41) and clinical
(14) investigations, elevations in CO were observed in the
present study following sustained levosimendan treatments.
This finding can be attributed to the positive inotropic effects
of levosimendan and the decreased afterload. However, the CO
was higher in group L than in group LG at 150 min. This
circulatory effect of glibenclamide may be explained by the
diminished vascular effect of levosimendan, leading to higher
afterload. The lack of a significant difference in MAP between
groups L and LG may support this explanation, since the
smaller elevations in CO associated with an increased afterload
result in MAP increases in group LG.
The effect of levosimendan on systemic blood pressure is
governed by the opposing contributions of the increased CO
that gives rise to the MAP as well as by the relaxation of the
systemic VSMC that results in a decrease in MAP. Although
the dominance of the VSMC relaxation was demonstrated in
earlier clinical investigations (30) and in experimental studies
in rats (41) and dogs (2), these factors seem to have compara-
ble effects in rabbits (9, 23); alternatively, the increase in CO
dominated (3, 21). Our data revealed a significant correlation
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between the changes in CO and MAP (Fig. 3), suggesting that
the increases in CO are responsible for the elevations in MAP,
rather than alterations in the systemic vascular smooth muscle
tone. We also observed slight elevations in HR uniformly in all
groups by the end of the experiments. This elevation may be
attributed to the gradual development of mild hypovolemia,
since intravenous administration of the different drugs and
saline (for PiCCO readings) may not have been sufficient to
account for the diuresis of the rabbits and the fluid loss
resulting from excessive salivation during the MCh challenges.
The mild tachycardia was not likely to bias the main findings
for the respiratory mechanics.
Bronchial effects of levosimendan. An important finding of
the present study is the strong ability of levosimendan to
protect against MCh-induced bronchospasm. The bronchopro-
tective potential demonstrated in the present study is in accor-
dance with earlier results obtained with isolated guinea pig
tracheal rings (12). In the guinea pig study, however, levosi-
mendan was added to an organ bath containing a tracheal ring
after establishing bronchospasm. Thus, the experimental ap-
proach allowed only the assessment of the ability of this
inodilator to acutely reverse an existing ASMC contraction. In
addition, the use of isolated tracheal rings as an experimental
model does not allow an overall picture of the entire bronchial
tree, and the lack of systemic effects precludes a comprehen-
sive overview of the cardiopulmonary effects of levosimendan
at an organ level. Furthermore, adding levosimendan to an
organ bath does not represent a clinical situation either in dose
or administration regimen.
The current results significantly extend our knowledge of the
bronchial effects of levosimendan. Because the onset time of
levosimendan is relatively long (22), the study protocol was
designed to characterize the preventive rather than the acute
treatment potential of levosimendan. Such an approach may
have clinical relevance in the perioperative care of patients
with heart failure, which is often associated with an elevated
bronchial tone (7). Lung mechanics may further deteriorate
perioperatively as a consequence of airway manipulation and
tracheal suctioning (33), fluid shifts (42), blood transfusion
(15), lung tissue damage (46), or systemic hypothermia (1).
Likewise, cardiac surgery with cardiopulmonary bypass is
known to trigger perioperative bronchial exacerbation (1), with
particularly severe cardiopulmonary consequences in patients
with airway hyperresponsiveness. All of these adverse respi-
ratory complications elevate work of breathing that might
necessitate prolonged mechanical ventilation.
The MCh-induced responses in Raw were dramatically in-
hibited by levosimendan infusion. Because Raw primarily re-
flects the flow resistance of the central conducting airways (5),
the ability of levosimendan to prevent proximal airway con-
striction can be anticipated. MCh also induced decreases in Iaw,
suggesting the enhancement of ventilation heterogeneities in
the lung periphery (35). Because levosimendan eliminated
these changes, it can be inferred that levosimendan might also
prevent the constriction of small peripheral airways.
The bronchoprotection effect of levosimendan vanished with
the prior administration of glibenclamide, demonstrating that the
relaxation of the ASMC by levosimendan was mediated by KATP
channels. This finding suggests that other mechanisms attrib-
uted to levosimendan in the relaxation of VSMC, such as the
inhibition of the phosphodiesterase III pathway (31), do not
play a role in the ASMC response in this species. Thus, the
mechanism responsible for the bronchoprotective potential of
levosimendan resembles that of volatile anesthetic agents that
have also been shown to induce bronchodilation by opening
KATP channels (8, 47).
Effects of levosimendan on the viscoelastic parameters of
respiratory tissues. We observed another important benefit of
levosimendan related to its ability to prevent MCh-induced
elevations in the viscoelastic parameters of the respiratory
tissues. Levosimendan has been shown to alleviate the devel-
opment of lung edema (39). Thus, the significant inhibition of
the MCh-induced elevations in G and the decreases in H may
have been attributed to intrinsic changes in tissue viscoelastic-
ity because of altered fluid content of the respiratory tissues.
Moreover, indirect mechanisms associated with prevention of
lung volume loss by inhibiting peripheral airway closures
might have also contributed to the observed effects of levosi-
mendan on the G and H responses. Interestingly, the ability of
levosimendan to prevent MCh-induced elevations in respira-
tory tissue damping and stiffness is more pronounced than that
of the volatile anesthetic agents, where opening the KATP
channels has little (24) or no effect on this lung compartment
(17, 28). This feature of levosimendan confirms its potent
beneficial action on the lung periphery, as outlined above.
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Limitations. One limitation of our results related to the
experimental protocol warrants discussion. To avoid prolonged
mechanical ventilation that could potentially interfere with the
other interventions, a somewhat shorter administration period
of clinically relevant concentrations of levosimendan was ad-
opted in the present study than is applied in routine clinical
settings (30, 36). This administration was in accordance with
previous protocols applied in rabbits (48) and reproduced the
well-established circulatory effects of levosimendan. Hence,
our approach was appropriate to investigate the pulmonary
effects of this agent.
Another possible limitation of our impedance data is related
to the measurement of the total respiratory system, including
pulmonary and chest wall compartments (43). Because rabbits
were under complete muscle relaxation during the entire pro-
tocol, the possible effects of levosimendan on the diaphragm
and/or on the chest wall muscles (10, 40, 45) were completely
absent. Therefore, the changes in the tissue mechanical param-
eters were of pulmonary origin. However, the magnitude of
this change was underestimated by the amount proportional to
the contribution of the chest wall to the total respiratory tissue
parameters, which is ~35–45% in smaller rodents (26, 34).
Summary and conclusions. The results of the present study
demonstrate the strong ability of levosimendan to protect
against MCh-induced changes in respiratory system mechan-
ics. The measurement of mechanical parameters reflecting the
entire bronchial tree revealed that levosimendan prevents cen-
tral airway constriction and might prohibit the enhancement of
ventilation heterogeneities in peripheral airways. Moreover,
the beneficial effects of levosimendan on the lung periphery
were also reflected in its ability to prevent elevations in
respiratory tissue damping and stiffness. This protective effect
of levosimendan was caused by opening KATP channels, as
demonstrated by the fact that the effect was completely elim-
inated by a prior administration of the KATP channel blocker,
glibenclamide. Levosimendan elevates CO and improves myo-
cardial oxygen balance combined with a strengthened dia-
phragm function (10). The association of these well-known
circulatory effects with the currently demonstrated beneficial
changes in respiratory mechanics might decrease the oxygen
demand of spontaneous breathing. This multimodal cardiore-
spiratory benefit has a potential of shortening the time of
invasive ventilation following its application.
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